Table of Contents
Overview
New York, NY – July 23, 2025 – The Global Apheresis Market size is expected to be worth around US$ 6.2 Billion by 2033, from US$ 3.5 Billion in 2023, growing at a CAGR of 5.9% during the forecast period from 2024 to 2033.
The global apheresis market is experiencing steady growth, supported by increasing adoption of blood component separation techniques across various medical disciplines. Apheresis, a specialized procedure used to separate and remove targeted components from the blood, has become a critical tool in both therapeutic and donor-related applications.
The rising prevalence of autoimmune disorders, hematologic diseases, and neurological conditions has contributed to greater demand for therapeutic apheresis procedures. Additionally, the use of apheresis in managing organ transplant recipients and patients undergoing chemotherapy has expanded its clinical relevance.
Continuous advancements in apheresis technology particularly in automated systems and device safety are improving treatment precision and patient outcomes. The demand for plasmapheresis and leukapheresis is notably rising in hospital-based settings, while blood banks increasingly utilize plateletpheresis to ensure a stable supply of high-quality blood components.
North America maintains a leading position in the global market, attributed to its robust healthcare infrastructure, high awareness of blood-related therapies, and favorable clinical guidelines. Meanwhile, the Asia-Pacific region is emerging as a key growth area, fueled by healthcare modernization, increased disease awareness, and improved access to specialized treatments.
As healthcare systems continue to recognize the therapeutic value of apheresis across multiple specialties, the market is expected to maintain positive momentum over the coming years.
Key Takeaways
- Market Growth Outlook: The global apheresis market is expected to witness consistent expansion, with projections indicating a compound annual growth rate (CAGR) of 5.9% from 2024 to 2033, reaching a market size of approximately US$ 6.2 billion by the end of the forecast period.
- Regional Leadership: North America emerged as the dominant regional market in 2023, accounting for over 36.3% of the global share. The market value in this region was recorded at approximately US$ 1.3 billion, supported by advanced healthcare infrastructure and strong procedural adoption rates.
- Product Segment Insights: The devices segment led the global apheresis market in 2023, capturing 63.7% of the total share. These devices are integral to both blood component separation and therapeutic applications, driving procedural efficiency and safety.
- Procedure Type Analysis: Plasmapheresis remained the most widely adopted apheresis procedure in 2023, accounting for 42.9% of the market share. It is particularly utilized in the treatment of autoimmune and chronic neurological conditions, such as myasthenia gravis.
- Technology Utilization: Centrifugation technology continued to dominate the market in 2023, holding 66.2% share. Its effectiveness in separating blood components based on density makes it the preferred method across clinical and donor settings.
- Application Focus: Apheresis procedures targeting hematological disorders, including leukemia and lymphoma, constituted 35.9% of the market in 2023. These procedures play a critical role in disease management and supportive care.
Segmentation Analysis
- Product Type Analysis: In 2023, the Devices segment led the apheresis market, accounting for over 63.7% of the product type share. These devices play a crucial role in blood component separation for both therapeutic use and donations. Their dominance is supported by advancements that enhance procedure safety and efficiency. Hospitals and blood centers rely heavily on these systems for plasma collection and leukapheresis. Regulatory approvals for next-generation devices further reinforce the segment’s strength, indicating sustained growth driven by innovation and clinical demand.
- Procedure Analysis: Plasmapheresis was the leading procedure in 2023, comprising over 42.9% of the market, primarily due to its widespread use in treating autoimmune and chronic conditions such as myasthenia gravis. Leukapheresis followed closely, essential in oncology and transplant care. While plateletpheresis and erythrocytapheresis represent smaller shares, they remain vital in specific clinical settings. Less common procedures like lipid apheresis and stem cell harvesting underscore the adaptability of apheresis in addressing diverse, specialized therapeutic needs across the healthcare spectrum.
- Technology Analysis: Centrifugation dominated the technology segment in 2023 with more than 66.2% market share, driven by its superior efficiency in separating blood components by density. This method is widely used in hospitals and blood banks due to its speed and reliability, especially in plasma and platelet collection. Membrane separation, while less prevalent, offers a gentler alternative by filtering components based on size. As innovation advances, membrane-based systems may see increased adoption for long-term treatments requiring high cell integrity.
- Application Analysis: In 2023, hematological disorders led the application segment with over 35.9% market share, due to the high demand for apheresis in treating leukemia, lymphoma, and related conditions. Neurological applications are also expanding, with procedures like plasma exchange aiding in the management of multiple sclerosis and myasthenia gravis. Apheresis further benefits autoimmune, renal, cardiovascular, and metabolic disorders by removing pathogenic substances. This broad therapeutic utility highlights apheresis as an essential intervention across critical and chronic care settings.
Market Segments
By Product Type
- Devices
- Disposables
By Apheresis Procedure
- Leukapheresis
- Plasmapheresis
- Plateletpheresis
- Erythrocytapheresis
- Other Apheresis Procedures
By Technology
- Centrifugation
- Membrane Separation
By Application
- Renal Disorders
- Hematological Disorders
- Neurological Disorders
- Autoimmune Disorders
- Other Applications
Regional Analysis
In 2023, North America maintained a leading position in the global apheresis market, accounting for over 36.3% of the total share, with a market value exceeding US$ 1.3 billion. This dominance can be attributed to the region’s well-established healthcare infrastructure, which includes globally recognized hospitals and research institutions that facilitate the widespread adoption of apheresis procedures in both therapeutic and donor settings.
The high burden of chronic illnesses particularly cancer, autoimmune, and hematologic disorders continues to drive clinical demand for advanced treatment modalities such as apheresis. These procedures are increasingly integrated into standard care protocols, reinforcing the region’s dependency on apheresis systems and devices.
Additionally, strong governmental support, favorable reimbursement structures, and consistent funding for medical innovation have accelerated the development and deployment of next-generation apheresis technologies. North American medical device manufacturers play a pivotal role in advancing system capabilities, improving both patient safety and procedural efficacy.
Education and training programs for healthcare professionals further ensure the skilled execution of apheresis treatments. Moreover, high per capita healthcare expenditure and broad insurance coverage enable access to these complex procedures across diverse patient populations. Collectively, these factors underscore North America’s continued market leadership and its role as a hub for innovation and application in the apheresis industry.
Emerging Trends
- Stabilized Blood Collections with Apheresis Uptick: In 2023, the U.S. collected approximately 11.6 million units of whole blood and apheresis RBCs, a slight 1.7% decline from 2021, with 1.26 million platelet units involved in apheresis processes a 3.6% increase in platelets and a large 49.2% rise in pathogen-reduced platelet treatments.
- Rising Use of Pathogen-Reduced Platelets: Pathogen-reduced platelet units reached 1.26million in 2023, marking a 49% increase from 2021. This indicates heightened focus on blood safety and infection control during transfusions.
- Growth in Apheresis RBC Collections: Between 2019 and 2021, apheresis-collected red blood cells grew from 1.8million to 1.93million units, a 7.3% increase. The trend suggests increasing preference for component-specific donation.
- Advanced Technology Adoption: New systems like Spectra Optia and immunoadsorption techniques (e.g., protein A columns) are being adopted widely to improve separation efficiency and treatment precision.
- Pediatric Adaptation and Safety Focus: Specialized equipment and protocols are now standard in pediatric apheresis to manage risks like blood volume loss, hypocalcemia, and catheter infections in smaller patients.
Use Cases
- Plateletpheresis (Donor Collection)
- Yields 6–10 times more platelets than pooled donations.
- Quality standards: ≥3×10¹¹ platelets per collection, pH ≥6.2.
- Therapeutic Plasma Exchange (Plasmapheresis)
- Treats autoimmune disorders: Guillain-Barré syndrome, Goodpasture’s syndrome, myasthenia gravis, and TTP.
- Also used for severe COVID-19, as weak but promising evidence suggests some benefit.
- Leukapheresis
- Removes excess white cells in leukemia or leukostasis.
- Used to collect granulocytes (\~1×10¹cells) for transfusion, particularly in treatment-resistant infections.
- Stem Cell Harvesting (PBSC Collection)
- Collects hematopoietic stem cells for transplants after mobilization with agents like G-CSF.
- Clinical trial NCT00562601 studies use in collecting both plasma and WBCs.
- LDL/Lp(a) Apheresis
- Clears LDL-cholesterol and lipoprotein(a) in patients with familial hypercholesterolemia (FH).
- Considered Class I by apheresis societies; supported by CMS public comments to expand coverage.
Conclusion
The global apheresis market is witnessing sustained growth, driven by increasing adoption of therapeutic and donor-specific procedures across diverse clinical settings. Advancements in automated technologies, rising prevalence of chronic and autoimmune diseases, and expanded applications in oncology, neurology, and transplantation are supporting broader utilization.
North America leads the market due to its strong healthcare infrastructure and innovation capacity, while the Asia-Pacific region is rapidly emerging. Rising use of pathogen-reduced platelets, growing RBC collections, and pediatric-specific protocols highlight evolving trends. As apheresis becomes more integral to modern care pathways, the market is projected to continue expanding steadily through 2033.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
